Floatz logo

Bendamustine

Thyroid Gland Carcinoma

National Cancer Institute (NCI)Small moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

31 Active assets in the Thyroid Gland Carcinoma cohort.

Asset / SponsorPhaseRating
FLUDEOXYGLUCOSE
Jonsson Comprehensive Cancer Center
Phase 2B
Dabrafenib
National Cancer Institute (NCI)
Phase 2CCC
Crizotinib
National Cancer Institute (NCI)
Phase 2CCC
Nivolumab
National Cancer Institute (NCI)
Phase 2CCC
Osimertinib
National Cancer Institute (NCI)
Phase 2CCC

View all 33 →

Same molecule, other indications

Bendamustine is also rated in:

mantle cell lymphomaDormant
BBB
Indicative ·
74 / 100
View asset →
Hodgkins lymphomaDormant
BBB
Indicative ·
73 / 100
View asset →
diffuse large B-cell lymphomaDormant
BB
Indicative ·
71 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →